The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Ask the ExpertFull Access

Management of Adolescent Substance Use Disorders, With an Emphasis on Cannabis Use Disorders

Substance use is commonly first experienced in adolescence (1), a time of rapid brain development (2). Yet, brain development throughout adolescence is functionally imbalanced. The limbic system that drives sensation seeking, reward, and impulsivity is already developed in early adolescence, whereas the prefrontal cortex (PFC) that provides the individual with impulse control, judgment, and decision making requires development well into young adulthood (3). Functional MRI (fMRI) studies that include measures obtained during go/no-go paradigms (a measure of inhibitory control) report sensation seeking to be high among adolescents versus low to medium among adults and adolescent impulsivity to be medium to high versus low to medium in adults (4); fMRI observations of a blunting of PFC inhibition circuitry in adolescents is now considered a measure of risk for the development of subsequent substance use disorders (5).

Alcohol, cannabis, and tobacco are the most common substances used by adolescents in the United States. In 2017, 7.4 million (1 in 5) individuals ages 12 to 20 drank alcohol in the past month, with 1 in 8 being binge drinkers within the past month; findings for 2015 and 2016 were similar (6). Decreases have occurred for several substances across eighth, 10th, and 12th graders, including synthetic cannabinoids, so-called bath salts (cathinones), and the prescription opioids OxyContin and Vicodin (1). Whereas cigarette smoking by adolescents has continued to decline, recent data suggest that the often flavored nicotine products, including E-cigarettes, may contribute to increases in new initiations to cigarette use (7). Although adolescent use of inhalants (vapors from toxic substances such as butane) is less than that of cigarettes, inhalant-induced neurobiological damage is so severe that the 2017 increase of 4.7% in inhalant use by eighth graders (1) is of significant concern.

Regarding cannabis, in 2017, adolescents in the combined eighth, 10th, and 12th grades increased cannabis use by 1.3%, to a total of 23.9% across the three grades (annual marijuana prevalence is 10%, 26%, and 37% in grades 8, 10, and 12, respectively) (1). Furthermore, almost one in every 16 high school seniors (5.8%) uses marijuana daily (1), and there is an early report of increases in daily use among adolescents in one of the first two states that have legalized cannabis (8). Cannabis is perceived across the United States as a safe recreational drug, yet frequent and heavy cannabis use in young adulthood has been shown to increase the risk for subsequent development of psychosis (9) as well as anxiety disorder (adjusted odds ratio [OR]=3.2, 95% confidence interval [CI]=1.1–9.2), but not depression, and cannabis use disorder (adjusted OR=2.2, 95% CI=1.1–4.4) (10).

In addition, a 2017 published study (11) assessed 65 adolescent females and males for brain resting-state functional connectivity between the caudal anterior cingulate cortex and superior frontal gyrus across time. Whereas increases in resting-state functional connectivity were present in the healthy control group, decreases were found in the individuals with cannabis use disorder and tested negative for cannabis. In addition, the smallest levels of connectivity were found in the cannabis users with the highest levels of prestudy cannabis use; the cannabis users also manifested measures of a lower intelligence quotient and slower cognitive function.

The most effective psychosocial treatment for cannabis use disorder appears to be combined cognitive-behavioral therapy and motivational enhancement therapy (12). A meta-analysis of 23 international randomized controlled trials involving 4,045 participants demonstrated optimal outcomes if the interventions included more than four sessions delivered for longer than one month, plus abstinence-based incentives. The patients receiving these sessions reported significantly fewer days of cannabis use in the previous 30 days (95% CI=3.08–8.26; N=1,144 participants). Treatment outcomes of cannabis or other substance use disorders are significantly worsened when patients manifest comorbid depressive disorder or posttraumatic stress disorder (13).

The National Institute on Drug Abuse has outlined 13 principles (14), based on clinical research, which are summarized below into four guidelines for effective assessment and treatment of adolescents.

  1. Substance use or substance use disorder is identified as soon as possible; once identified, other mental health conditions, violence, child abuse, or risk of suicide are to be identified and addressed. Testing for sexually transmitted diseases, including HIV, hepatitis B, and hepatitis C, is important.

  2. The treatment process is tailored to address the unique needs of the adolescent and the needs of the whole person; assessment and treatment also include the family and community.

  3. Drug use monitoring occurs at the beginning of treatment, throughout treatment, and as part of follow-up assessment. Treatment includes psychosocial/behavioral treatment and has the potential of being combined with pharmacotherapy to treat substance use and/or comorbid mental disorders.

  4. Adolescents benefit from a drug use intervention, regardless of whether a substance use disorder exists, annual medical or otherwise scheduled visits present an ideal opportunity to ask adolescents about substance use, and legal interventions and sanctions and/or family pressure helps adolescents to enter and remain in treatment.

When possible, the treatment team ideally comprises the clinician(s), parents, potentially other family members or significant others, and the adolescent all working together. A critical finding of clinical research is that adolescents who use substances by age 13, especially males, are at significant risk to develop a substance use disorder later (15). A most important challenge for parents is maintaining awareness of their adolescents’ companions and where their children are when not at home or school; this is a robust predictor of risky adolescent behavior, including using drugs and alcohol (16). Protective and risk factors have been identified from the perspective of the family, the individual, and the community and schools. Family-based protective factors include the provision of structure, limits, rules, monitoring, and predictability; the presence of supportive relationships with family members; and communication of clear expectations for behavior and values (17).

Department of Psychiatry and Behavioral Neurosciences, Cedars-Sinai Medical Center, Los Angeles.
Send correspondence to Dr. Wilkins ().

Dr. Wilkins reports no financial relationships with commercial interests

References

1 Johnston LD, Miech RA, O’Malley PM, et al.: Monitoring the Future: National Survey Results on Drug Use, 1975–2017. 2017 Overview: Key Findings on Adolescent Drug Use. Ann Arbor, Institute for Social Research, University of Michigan, 2018CrossrefGoogle Scholar

2 Winters, KC, Botzet, AM, Stinchfield, R, et al..: Adolescent substance abuse treatment: a review of evidence-based prevention and treatment; in Adolescent Substance Abuse—Evidence-Based Approaches to Prevention and Treatment: Issues in Children’s and Families’ Lives, 2nd ed. Edited by Leukefeld CG, Gullotta TP. Cham, Switzerland, Springer, 2018CrossrefGoogle Scholar

3 Giedd JN, Rapoport JL: Structural MRI of pediatric brain development: what have we learned and where are we going? Neuron 2010; 67:728–734CrossrefGoogle Scholar

4 Steinberg L, Albert D, Cauffman E, et al.: Age differences in sensation seeking and impulsivity as indexed by behavior and self-report: evidence for a dual systems model. Dev Psychol 2008; 44:1764–1778CrossrefGoogle Scholar

5 Heitzeg MM, Cope LM, Martz ME, et al.: Neuroimaging risk markers for substance abuse: recent findings on inhibitory control and reward system functioning. Curr Addict Rep 2015; 2:91–103CrossrefGoogle Scholar

6 (2018). Key Substance Use and Mental Health Indicators in the United States: Results from the 2017 National Survey on Drug Use and Health. HHS Publication No. SMA 18-5068, NSDUH Series H-53. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, 2018. https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHFFR2017/NSDUHFFR2017.pdfGoogle Scholar

7 Leventhal AM, Strong DR, Kirkpatrick MG, et al.: Association of electronic cigarette use with initiation of combustible tobacco product smoking in early adolescence. JAMA 2015; 314:700–707CrossrefGoogle Scholar

8 Cerdá , M, Wall, M, Feng, T, et al.: Association of state recreational marijuana laws with adolescent marijuana use. JAMA Pediatr 2017;171:142–149CrossrefGoogle Scholar

9 Colizzi M, Murray R: Cannabis and psychosis: what do we know and what should we do? Br J Psychiatry 2018; 212:195–196CrossrefGoogle Scholar

10 Degenhardt L, Coffey C, Romaniuk H, et al.: The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction 2013; 108:124–133CrossrefGoogle Scholar

11 Camchong J, Lim KO, Kumra S: Adverse effects of cannabis on adolescent brain development: a longitudinal study. Cereb Cortex 2017; 27:1922–1930Google Scholar

12 Gates PJ, Sabioni P, Copeland J, et al.: Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev 2016; (5):CD005336Google Scholar

13 Najt P, Fusar-Poli P, Brambilla P: Co-occurring mental and substance abuse disorders: a review on the potential predictors and clinical outcomes. Psychiatry Res 2011; 186:159–164CrossrefGoogle Scholar

14 Principles of Adolescent Substance Use Disorder Treatment: A Research-Based Guide. NIH Pub No 14-7953. Bethesda, MD, National Institute on Drug Abuse, 2014. https://d14rmgtrwzf5a.cloudfront.net/sites/default/files/podata_1_17_14.pdf. Accessed Feb 20, 2019Google Scholar

15 Grant BF, Dawson DA: Age of onset of drug use and its association with DSM-IV drug abuse and dependence: results from the National Longitudinal Alcohol Epidemiologic Survey. J Subst Abuse 1998; 10:163–173CrossrefGoogle Scholar

16 Jones JD, Ehrlich KB, Lejuez CW, et al.: Parental knowledge of adolescent activities: Links with parental attachment style and adolescent substance use. J Fam Psychol 2015; 29:191–200CrossrefGoogle Scholar

17 Risk and Protective Factors for Mental, Emotional, and Behavioral Disorders Across the Life Cycle. https://youth.gov/youth-topics/substance-abuse/risk-and-protective-factors-substance-use-abuse-and-dependence.pdfGoogle Scholar